Event-Driven Stocks

Mural Oncology plc

MURACompleted

Spin-offSpun off from AlkermesALKSNasdaq

The two companies

Parent
AlkermesALKSNasdaq
Pharmaceutical Preparations
↓ spun off ↓

Open either company's hub for its full SEC financials, ratios, ownership, filings, and every other event it's been part of.

Sector
Healthcare
Industry
Pharmaceutical Preparations
Exchange
State of incorporation
L2
Record date
Distribution date
November 14, 2023
Ratio
1:10
Parent sector
Pharmaceutical Preparations
Form
10-12B/A
Filed
October 26, 2023

Financials — parent vs spin-off

SEC XBRL · latest year
AlkermesFY25
Revenue
$1.48B
Operating income
$254M
Net income
$242M
Total assets
$2.49B
Equity
$1.82B
Mural Oncology plcFY24
Revenue
Operating income
−$138M
Net income
−$129M
Total assets
$169M
Equity
$141M

Latest reported figures from each company's own SEC filings — the parent after the separation and the spin-off as a standalone. Full multi-year history on each company hub.

Spin-off signals

score 2/6 favorable · factors, not advice
  • Focus-increasingNo — both Healthcare

    Spin-offs into a different sector than the parent (pure-plays) have historically outperformed diversifying ones.

  • Leverage (liabilities/assets)17%

    A heavy debt load loaded onto the spin-off is a known risk; a clean balance sheet is favorable.

  • Return on capital employed-96.6%

    EBIT ÷ capital employed — the quality metric the spin-off scorecard research weighs most.

  • Tax-basis reportNone found

    A Form 8937 (basis allocation) accompanies tax-free §355 spin-offs — favorable for taxable holders.

  • Insider buying (post-spin)None recorded

    Officers/directors buying their own newly independent shares (Form 4) has historically preceded outperformance.

  • Time since spin-off2.6 years

    Studies find the spin-off return premium concentrates in roughly the first one to three years.

Factors the spin-off research literature (Greenblatt; Cusatis-Miles-Woolridge; Desai-Jain) associates with outcomes — computed from this company's own SEC filings, shown as factors, not a recommendation. The premium is debated and not guaranteed. How we compute these ↗

Filings & documents

Every entry traces to SEC EDGAR. The Information Statement is the primary source; the links below open the full filing and each company's complete filing history.